Autism Diagnosis and Proteomics: Are Blood-Based Biomarkers Within Reach?
Proteomics reveals protein signatures that could enable earlier, more objective autism diagnosis.
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by differences in social communication and behavior. Despite years of research, diagnosis still relies primarily on behavioral assessments, which can be subjective and often delay identification until symptoms are clearly observable. The absence of clinically established biomarkers remains a big challenge.
Recently, researchers have turned to molecular approaches to identify objective, biology-based indicators of ASD. Among these, proteomics—the large-scale study of proteins—has emerged as a promising tool.
One researcher at the forefront of this field is Dr. Dwight German, a professor at the University of Texas Southwestern Medical Center, whose work explores how protein-level changes in blood and other tissues could enable earlier and more precise diagnosis of ASD.
This article examines the scientific rationale behind proteomics in ASD, including recent advances in biomarker discovery and the challenges that must be addressed before these approaches can reach the clinic.
Why use proteomics to study autism?
Autism is famously heterogeneous, with no single genetic mutation or environmental factor accounting for the breadth of the spectrum. This complexity has led researchers to explore multiomic approaches, integrating genomics, metabolomics, and proteomics to better understand the underlying biology.
While genomics captures inherited risk and transcriptomics reflects gene expression, proteomics provides direct insight into the molecules that execute cellular functions. Proteins are also sensitive to environmental influences and post-translational modifications, making them ideal candidates for studying complex, multifactorial conditions like ASD. Many proteins can also be measured via non-invasive or minimally invasive diagnostic approaches in accessible biofluids such as blood, urine, and saliva, making them uniquely suited for clinical translation.
“Because it is possible to screen for more proteins in the blood (>10,000), it is now possible to gain further insight into autism for both diagnosis and treatment,” said German.
Recent large-scale analyses have begun to identify consistent protein-level differences between individuals with ASD and neurotypical controls. Across multiple tissue types, several proteins—including FLOT2, ApoE, EHD3, VCL, and GSN—have been consistently dysregulated.
Beyond individual proteins, proteomic studies have highlighted broader pathway-level disruptions, pointing to alterations in glycolysis and gluconeogenesis, carbon metabolism, and glutathione metabolism. These pathways are closely linked to energy production, oxidative stress, and cellular homeostasis—processes that have been implicated in neurodevelopmental disorders.
Key metabolic pathways linked to autism
- Glycolysis and gluconeogenesis: Processes that regulate how cells generate and store energy. Disruptions may affect how the brain meets its high energy demands during development.
- Carbon metabolism: A network of reactions involved in processing nutrients to produce energy and essential biomolecules. Alterations may reflect broader metabolic imbalance in ASD.
- Glutathione metabolism: Controls the production of glutathione, a key antioxidant that protects cells from oxidative stress. Dysregulation may contribute to increased cellular stress observed in ASD.
Proteomic biomarkers for autism diagnosis show strong potential
Researchers, including German, are now developing targeted proteomic panels with the aim of distinguishing individuals with ASD from controls. Rather than looking for a single “autism protein”, scientists are using groups of proteins that, when viewed together, create a high-probability diagnostic profile.
German and his colleagues identified 86 downregulated and 52 upregulated proteins in individuals with ASD using serum samples. From the data, they derived a 12-protein diagnostic panel capable of discriminating ASD cases with a high degree of accuracy.
“Proteomics and machine learning have enabled a blood test for ASD to be developed,” explained German. His specific protein panel demonstrated 87% accuracy for identifying ASD in boys. The team is currently in the process of validating this panel in a new sample of 100 ASD boys and 100 control boys, while simultaneously expanding their research to include demographics for girls.
As mentioned by German, one factor driving these advances is the integration of machine learning. Proteomic datasets are inherently high-dimensional, often comprising thousands of proteins measured across relatively small cohorts. Machine learning algorithms can identify complex patterns within this data, enabling the construction of predictive models that would be difficult to create using traditional statistical approaches.
Beyond single-study findings, there is recognition that combining multiple types of biological data may further enhance diagnostic performance. Multi-modal approaches that integrate proteomics with genomics and metabolomics are now seen as a way to capture the full complexity of ASD biology.
Tech Spotlight: High-Throughput Screening 2026
Explore reliable high-throughput screening workflows for vaccine and antibody discovery, covering assay design, validation and data analysis to improve reproducibility, data quality and candidate prioritization.View Webinar
The shift toward integrative models also reflects a broader trend in precision medicine, where the goal is not only to diagnose but to identify distinct subtypes so that interventions can be tailored to the individual. In the context of ASD, this approach could eventually support more personalized care pathways.
Challenges in translating proteomics into autism diagnostics
Despite the excitement surrounding proteomics-based biomarkers, none are clinically validated or approved for ASD diagnosis.
“The main opportunity for proteomics is to get an ASD blood biomarker on the market,” said German, but he acknowledged the challenges that remain.
Proteomic studies often vary in their methodologies, including sample preparation and data processing pipelines. These differences can lead to inconsistencies in reported biomarkers across studies, making it difficult to establish universally reliable signatures.
However, one of the biggest challenges is the biological diversity of autism itself.
“It may be that more than one ASD proteomic biomarker will be identified, that cover a greater percentage of cases on the spectrum,” said German.
Recent research suggests that the condition may encompass multiple biologically distinct subtypes, each with its own molecular profile. This raises the possibility that no single biomarker, or a single panel, may be sufficient to capture the full spectrum of ASD.
Circulating Immune Proteins in Liver Cancer Research
This webinar explores how circulating immune-related proteins can improve our understanding of hepatocellular and gallbladder cancer risk across diverse populations with viral hepatitis.View Webinar
Addressing this complexity will require larger, more diverse cohorts and carefully designed longitudinal studies. Tracking individuals over time could help distinguish between biomarkers that are stable indicators of risk and those that reflect disease progression.
While many studies focus on children who have already been diagnosed, the end goal is to identify ASD as early as possible—ideally in infancy or even at birth.
“A current challenge is to be able to identify ASD in newborn children, which would enable early treatment,” said German.
German’s current work also investigates the exposome—the measure of all the environmental exposures of an individual in a lifetime. By measuring over 200 environmental contaminants in the blood (including pesticides, plastics, and toxins), the team hopes to understand how environmental triggers interact with the proteome to influence ASD risk.
The future of proteomics in autism diagnosis and personalized care
By revealing consistent differences in protein expression and highlighting disrupted biological pathways, proteomic studies are moving ASD diagnostics from subjective observation to objective science.
“In the future, it should be possible to identify ASD and ASD-subtypes using blood testing. The earlier the identification, the earlier the treatment and the less severe the symptoms over time,” German said.
However, the transition from research to standard of care requires patience. Clinical adoption will need further large-scale replication, longitudinal studies to see how these proteins change over time, and a harmonization of data across international populations.
Looking ahead, the integration of proteomics with multiomic data and advanced computational modeling could change how ASD is diagnosed and managed. By bridging the gap between molecular biology and clinical practice, these efforts may enable earlier detection and more personalized interventions.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
